Identification of novel therapeutics for tuberculosis combining cheminformatics,

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$149,382.00
Award Year:
2010
Program:
STTR
Phase:
Phase I
Contract:
1R41AI088893-01
Agency Tracking Number:
R41AI088893
Solicitation Year:
2010
Solicitation Topic Code:
NIAID
Solicitation Number:
PHS2010-2
Small Business Information
SRI INTERNATIONAL
1633 Bayshore Hwy, Suite 342, BURLINGAME, CA, -
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
149823846
Principal Investigator:
SEAN EKINS
(269) 930-0974
SEAN@GENEGO.COM
Business Contact:
SEAN EKINS
(650) 859-4979
grants@sri.com
Research Institution:
Sri International

333 RAVENSWOOD AVE
MENLO PARK, CA, 94025-3493
() -
Domestic nonprofit research organization
Abstract
DESCRIPTION (provided by applicant): This Small Business Technology Transfer Phase I project entitled Identification of novel therapeutics for tuberculosis combining cheminformatics, diverse databases and logic-based pathway analysis describes the development of software that will facilitate new drug discovery efforts for Mycobacterium tuberculosis (TB). The amount of research performed on TB compared with other known pharmaceutical targets (cancer, heart disease, diabetes etc.) is limited primarily to disparate academic groups and small groups in big drug companies. There is no repository of global knowledge on TB that could assist in drug development efforts. We propose to develop a prototype system to facilitate new drug discovery efforts for TB using novel logical inference techniques developed by scientists at SRI International, which would be linked with knowledge which has been assembled by the curation of diverse biological data types and computational prediction by Collaborative Drug Discovery (CDD). This tool will be used to aid the Identification of novel therapeutics for Tuberculosis by combining cheminformatics, diverse databases and logic-based pathway analysis. It will represent a synergistic computational tool for hypotheses testing, knowledge sharing, data archiving, data mining and drug discovery. We expect a combined product would have considerable impact on TB research enabling further experimental validation of hypotheses in phase II. As TB is one of the world's deadliest diseases the value of our proposal would be high. The societal impact would be the ability to mine the deposited data, search for new potential targets and lead molecules and bring the data and researchers to a single centralized location. PUBLIC HEALTH RELEVANCE: We propose to develop a prototype system to facilitate new drug discovery efforts for TB using novel logical inference techniques developed by scientists at SRI International, which would be linked with knowledge which has been assembled by the curation of diverse biological data types and computational prediction by Collaborative Drug Discovery (CDD). This tool will be used to aid the Identification of Novel Therapeutics for Tuberculosis by combining Cheminformatics, Diverse Databases and Logic-based Pathway Analysis. It will represent a synergistic computational tool for hypotheses testing, knowledge sharing, data archiving, data mining and drug discovery.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government